Company intelligence / Profile preview

Predix Pharmaceuticals

Lexington, Massachusetts, United Statesen.wikipedia.org ↗

Ownership: Private
Development stage: Phase 3

Overview

Predix advanced three internally discovered small-molecule drug candidates into clinical trials targeting CNS disorders and pulmonary hypertension. Its lead program was expected to enter pivotal Phase III trials for generalized anxiety disorder; other programs targeted Alzheimer’s disease and pulmonary arterial hypertension. The company merged with Epix Pharmaceuticals in a $90 million deal but ceased operations by July 2009 due to financial difficulties.

Therapeutic areas: PulmonologyPsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ax102

Preclinical

Partnerships

Schering AG had an option agreement related to joint agents developed by Epix-Schering after the merger. No major partnerships listed prior to acquisition.

Beyond the preview

Go deeper on Predix Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Predix Pharmaceuticals.

Explore the full profile